Page last updated: 2024-12-05

n,n'-dinitrosopiperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N'-dinitrosopiperazine: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8819
CHEMBL ID1332
SCHEMBL ID2353649
MeSH IDM0086218

Synonyms (50)

Synonym
ai3-21352
ccris 6929
einecs 205-434-6
hsdb 5091
dinitrosopiperazin [german]
brn 0135106
dnpz
dinitrosopiperazine
n-dinitrosopiperazine
wln: t6n dntj ano dno
140-79-4
dinitrosopiperazin
n,n'-dinitrosopiperazine
usaf do-36
piperazine,4-dinitroso-
nsc339
carcinogen
1,4-dinitrosopiperazine
nsc 339
nsc-339
piperazine, 1,4-dinitroso-
nn'-dinitrosopiperazine
FT-0667601
CHEMBL1332
AKOS006281474
cas-140-79-4
NCGC00260328-01
dtxsid0020527 ,
tox21_202782
dtxcid00527
gu48c6581i ,
5-23-03-00225 (beilstein handbook reference)
unii-gu48c6581i
1,4-dinitrosopiperazine [hsdb]
SCHEMBL2353649
(s,s)-(-)-2,3-dihydroxy-n,n,n,n-tetramethylsuccinamide
WNSYEWGYAFFSSQ-UHFFFAOYSA-N
1,4-dinitroso-piperazine
1,4-dinitrosopiperazine (acd/name 4.0)
dinitrosopiperazin(german)
J-007422
FT-0667602
Q27279283
n,n-dinitrosopiperazine
HY-136433
CS-0129402
EN300-104009
n,n'-dinitrosopiperazine (dmp)
piperazine, 1,4-dinitroso-; dnp; n,n'-dinitrosopiperazine; nsc 339
Z1198147437

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"01) respectively, though DNP was used alone in a much shortened inducing period at less dosage and without the use of carcinogenic promoter 12-O-tetradecanoylphorbol-13-acetate as usual."( Enhancive effect of N,N'-dinitrosopiperazine on inducing precancerous lesion on nasal and/or nasopharyngeal epithelia of TgN(p53mt-LMP1)/HT mice.
He, YC; Lu, FG; Tang, FQ; Tian, DF, 2009
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.00630.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID226732The compound was modelled in silico for carcinogenic potency; + = Carcinogen1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (45.00)18.7374
1990's6 (15.00)18.2507
2000's9 (22.50)29.6817
2010's7 (17.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.68 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other40 (97.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]